In this context, it is sobering to rethink the adjuvant administration of recombinant CSF2 to ameliorate therapy-induced neutropenia in CSF2-releasing cancers 49, such as myxofibrosarcomas with overexpressed and activated PAK1, which is at risk of detrimental cancer-promoting effect. Here, CSF2 is linked to myxofibrosarcoma.